Home > Press > Oxonica’s CEO Appointed to the Elementis Board
Oxonica Ltd announces today that its chief executive, Dr. Kevin Matthews has been appointed to the Board of Elementis plc, as a non-executive director with effect from 16th February 2005.
Oxonica’s CEO Appointed as a Non-executive Director to the Elementis Board
February 17, 2005
Oxonica Limited is a leading European technology group, with products already launched into the global market.
The company was spun-out in 1999 from the University of Oxford and is based in Oxford, England. Oxonica currently employs 30 professional staff and is lead by a strong and commercially experienced management team.
Oxonica’s mission is to develop commercial solutions from nanotechnology. It owns a diverse portfolio of demand driven products that offer substantial benefits to the target markets of environmental, healthcare and materials.
Lead products include:
- Envirox™ Fuel Borne Catalyst – A nanocataylst optimising fuel economy and reducing emissions
- Optisol™ UV Filter – A range of ultra-stable UVA absorbers with enhanced free radical scavenging, with immediate applications in sunscreens and other cosmetics
Oxonica is also active in searching for the next generation of products and is already engaged in developing transformational detection technologies which will enable a new generation of diagnostic products for the clinical diagnostic and life science markets.
In addition, the company is developing other UV absorber technologies into polymer systems and coatings, based on similar technologies to that used in Optisol™.
01865 856 728
Island House, Forest Road, Guernsey, GY8 0AB, UK
Tel +44 (0) 1481 233080
Fax +44 (0) 1481 233082
Copyright © Oxonica
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017
Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017
Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017
Video captures bubble-blowing battery in action: Researchers propose how bubbles form, could lead to smaller lithium-air batteries April 26th, 2017
180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017
Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017
Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017
Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016